British drug developer GW Pharmaceuticals Plc said its experimental cannabis-derived epilepsy drug met the main goal to reduce frequency of seizures in a late-stage study.

An experimental cannabis drug for treating schizophrenia, developed by UK-based GW Pharmaceuticals Plc, was found to be superior to a placebo in a mid-stage trial. The company’s UK-listed shares jumped 12.5 percent, while U.S.-listed shares were up 10 pct. The drug, cannabidiol, was tested in 88 patients with schizophrenia, who had failed to respond to […]